Base de dados : MEDLINE
Pesquisa : C11.187.183.200 [Categoria DeCS]
Referências encontradas : 3005 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 301 ir para página                         

  1 / 3005 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28455783
Autor:Shah-Hosseini K; Krudewig EM; Hadler M; Karagiannis E; Mösges R
Endereço:Institute of Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Cologne, Germany.
Título:Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study.
Fonte:Adv Ther; 34(6):1382-1397, 2017 Jun.
ISSN:1865-8652
País de publicação:United States
Idioma:eng
Resumo:INTRODUCTION: Allergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice. METHODS: In a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded. RESULTS: A total of 1482 patients aged 4-75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P < 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented. CONCLUSION: This study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication. FUNDING: Stallergenes GmbH.
Tipo de publicação: JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY


  2 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
PMID:28832741
Autor:Costa AXD; Gomes JÁP; Marculino LGC; Liendo VL; Barreiro TP; Santos MSD
Endereço:Cornea and External Eye Disease Clinic, Departamento de Oftalmologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Título:Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children.
Fonte:Arq Bras Oftalmol; 80(3):186-188, 2017 Jun.
ISSN:1678-2925
País de publicação:Brazil
Idioma:eng
Resumo:PURPOSE: To evaluate the use of supratarsal injection of triamcinolone acetonide in severe vernal keratoconjunctivitis (VKC) in children. METHODS: Patients included in this open clinical trial were those with severe VKC-associated with keratitis, gelatinous limbal infiltrates, and/or giant papillae, with a history of recurrence and resistance to conventional topical antiallergic agents. Patients were treated with a supratarsal injection of 20 mg triamcinolone acetonide. RESULTS: Analysis included 27 injections in 23 eyes of 17 patients with severe allergic keratoconjunctivitis. Mean age was 12.3 (range: 7-19) years. Mean follow-up time was 39.3 months (SD=19.21). In the 17 patients, the disease was successfully controlled for an average of 3.6 months (range: 1-16), during which allergy symptoms and signs were significantly improved, with complete resolution of lid edema and conjunctival chemosis, significant decline of pannus and keratitis, and reduction of giant papillae size. CONCLUSION: Treatment of severe, acute VKC in children with supratarsal injection of 20 mg triamcinolone acetonide showed satisfactory results and was well tolerated by patients; it may therefore constitute a safe option for severe and challenging cases. While full disease remission was not achieved, a significant improvement was found in ocular allergy symptoms and signs, with a reduction in the frequency of acute recurrences.
Tipo de publicação: CLINICAL TRIAL; JOURNAL ARTICLE
Nome de substância:0 (Glucocorticoids); F446C597KA (Triamcinolone Acetonide)


  3 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
PMID:28832739
Autor:Müller EG; Santos MSD; Freitas D; Gomes JÁP; Belfort R
Endereço:Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo, Brazil.
Título:Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.
Fonte:Arq Bras Oftalmol; 80(3):154-158, 2017 Jun.
ISSN:1678-2925
País de publicação:Brazil
Idioma:eng
Resumo:PURPOSE: To assess the efficacy of monotherapy using tacrolimus eye drops versus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC). METHODS: Randomized double-masked controlled trial comparing the efficacy of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 90 of follow-up. Visual acuity, intraocular pressure, and other complications were evaluated to assess safety and side effects. RESULTS: In total, 16 patients were included, with 8 enrolled in each group. Two patients from Group 2 were excluded from the analysis at days 45 and 90 because of corticosteroid use. Most patients were male (81.8%) and presented with limbal VKC (56.3%). There were statistically significant differences in favor of tacrolimus in the following severity scores: itching at day 90 (p=0.001); foreign body sensation at day 15 (p=0.042); photophobia at day 30 (p=0.041); keratitis at day 30 (p=0.048); and limbal activity at days 15 (p=0.011), 30 (p=0.007), and 45 (p=0.015). No relevant adverse effects were reported, except for a burning sensation with tacrolimus, though this did not compromise treatment compliance. CONCLUSION: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis.
Tipo de publicação: JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
Nome de substância:0 (Immunosuppressive Agents); 0 (Ophthalmic Solutions); Q2WXR1I0PK (Cromolyn Sodium); WM0HAQ4WNM (Tacrolimus)


  4 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28656804
Autor:Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
Endereço:a Division of Allergy and Clinical Immunology, Department of Medicine , East Tennessee Statement , Johnson City , TN , USA.
Título:Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
Fonte:Expert Opin Pharmacother; 18(11):1137-1143, 2017 Aug.
ISSN:1744-7666
País de publicação:England
Idioma:eng
Resumo:INTRODUCTION: Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available as oral, intranasal and ocular preparations. Most of the practical applications of olopatadine therapy focus on the treatment of allergic rhinoconjunctivitis via intranasal and ocular routes. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of children and adults. The articles that have been selected, evaluate the use of intranasal and ocular antihistamines and their role in allergic rhinoconjunctivitis. Expert opinion: Olopatadine is significantly more effective than placebos in relieving the symptoms of allergic rhinoconjunctivitis. It can function both as a viable alternative or addition to first line therapies such as intranasal steroids and oral antihistamines.
Tipo de publicação: JOURNAL ARTICLE; REVIEW
Nome de substância:0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists); 0 (Ophthalmic Solutions); 2XG66W44KF (Olopatadine Hydrochloride)


  5 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28604572
Autor:Rodgin SG
Endereço:*OD, MAc, FAAO Veterans Administration Medical Center, Boston, Massachusetts; Private Practice, Wayland, Massachusetts; and Adjunct Faculty, New England College of Optometry, Boston, Massachusetts.
Título:Food-Induced Red Eye.
Fonte:Optom Vis Sci; 94(7):775-780, 2017 Jul.
ISSN:1538-9235
País de publicação:United States
Idioma:eng
Resumo:PURPOSE: This article addresses the etiology of red eyes and a novel case of food-induced red eye. CASE REPORT: An 82-year-old white male patient reported 50 years of episodes of severe unilateral bulbar injection in either eye following ingestion of certain foods. Thinned scleras in this particular patient made the injection in his eyes more observable. Photodocumentation of this reaction after he ingested these foods is shown. CONCLUSIONS: It is hypothesized that this is a new explanation for an intermittent, unilateral, self-limited red eye-a food-induced red eye.
Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE


  6 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28593244
Autor:Hara Y; Shiraishi A; Sakane Y; Takezawa Y; Kamao T; Ohashi Y; Yasunaga S; Sugahara T
Endereço:Department of Ophthalmology, Ehime University School of Medicine, Shitsukawa, Toon, Ehime, Japan.
Título:Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge.
Fonte:Invest Ophthalmol Vis Sci; 58(7):2922-2929, 2017 Jun 01.
ISSN:1552-5783
País de publicação:United States
Idioma:eng
Resumo:Purpose: To evaluate the effects of mandarin orange yogurt containing nobiletin and ß-lactoglobulin on the allergic conjunctivitis induced by a conjunctival allergen challenge (CAC). Methods: Experiment 1 was performed on 26 asymptomatic patients (age, 25.3 ± 5.3 years) with proven seasonal allergic conjunctivitis due to cedar pollen. We compared the degree of conjunctivitis induced by CAC before and after ingesting mandarin orange yogurt for 2 weeks. Experiment 2 was a double-blind, placebo-controlled trial performed on 31 patients (age, 32.5 ± 12.2 years). A diet containing mandarin orange yogurt was compared to a diet containing yogurt lacking the mandarin orange on the conjunctivitis induced by CAC. The temperature of the inferior bulbar conjunctiva was measured before and 20 minutes after the CAC with an ocular surface thermographer (OST). The degree of conjunctival injection and chemosis was graded by slit-lamp biomicroscopy. The changes in the symptoms were evaluated by a questionnaire. Results: In experiment 1, the scores of redness (3.07 ± 3.03 vs. 1.05 ± 1.70), chemosis (2.84 ± 2.27 vs. 0.81 ± 1.11), itching (4.34 ± 3.05 vs. 1.39 ± 2.12), and temperature (0.73 ± 0.42°C vs. 0.45 ± 0.43°C) were significantly lower (P < 0.001) after a diet of mandarin orange yogurt for 2 weeks. In experiment 2, the scores of redness (1.03 ± 0.18 vs. 1.28 ± 0.52; P = 0.0156), itching (1.93 ± 1.92 vs. 2.82 ± 2.21; P = 0.0133), and surface temperature (0.54 ± 0.21°C vs. 0.31 ± 0.25°C; P < 0.001) were significantly lower in the mandarin orange yogurt group than in the control yogurt group. Conclusions: Mandarin orange yogurt can be an effective nutritional intervention for allergic conjunctivitis.
Tipo de publicação: JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
Nome de substância:0 (Allergens); 0 (Ophthalmic Solutions); 0 (Plant Oils)


  7 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28573997
Autor:Shetty R; Sureka S; Kusumgar P; Sethu S; Sainani K
Endereço:Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India.
Título:Allergen-specific exposure associated with high immunoglobulin E and eye rubbing predisposes to progression of keratoconus.
Fonte:Indian J Ophthalmol; 65(5):399-402, 2017 May.
ISSN:1998-3689
País de publicação:India
Idioma:eng
Resumo:We report two male children with persistent allergic eye disease (AED) and keratoconus (KC). Both presented with symptoms of vernal keratoconjunctivitis and decreased vision. In view of unrelenting AED, serum immunoglobulin E (IgE) quantification and identification of specific allergens were advised. Increased serum IgE levels were observed in both cases. Sunflower and sheep wool were identified as specific allergens for the first and second patient respectively by skin patch test. There was complete resolution of symptoms of AED in both patients following avoidance of causative allergens. However, the progression of KC in both eyes of the first patient and one eye of the second patient was observed. They were advised collagen cross-linking. Elevated serum IgE indicates the presence of systemic allergy. Avoiding implicated allergens help alleviate ocular symptoms. Using serum IgE and identifying specific allergen can guide in the treatment of AED and thus prevent progressive KC due to eye rubbing and resulting inflammation.
Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE
Nome de substância:0 (Allergens); 0 (Biomarkers); 37341-29-0 (Immunoglobulin E)


  8 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28380494
Autor:Buczylko K; van der Werf JF; Boot D; van Ree R
Endereço:NZOZ Centrum Alergologii, Lódz, Poland.
Título:Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Fonte:Int Arch Allergy Immunol; 172(3):183-186, 2017.
ISSN:1423-0097
País de publicação:Switzerland
Idioma:eng
Resumo:BACKGROUND: Early pollen flight and new allergens prolonging the pollen season means that the time for up-dosing of allergen-specific subcutaneous immunotherapy (SCIT) outside the pollen season becomes shorter. Hence, for patients who wish or need to be up-dosed faster, an accelerated induction regimen would provide a useful treatment option. METHODS: An accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals) was compared to conventional up-dosing (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals) using an allergoid birch pollen SCIT preparation. After up-dosing, the maintenance dose (0.5 mL) was given 3 times at biweekly intervals. The multicenter study was performed according to an open randomized, parallel-group design. RESULTS: A total of 123 birch pollen-allergic patients (81 adults and 42 adolescents) presenting with rhinitis or rhinoconjunctivitis with or without mild asthma (FEV1 >70%) were randomized to either the conventional registered up-dosing or an accelerated regimen. In total, 96.7 and 98.4% successfully reached the maintenance dose for the conventional and accelerated regimen, respectively, without relevant differences between adults and adolescents. Both regimens were safe and well tolerated. Furthermore, significant increases (similar in size) in specific IgG and IgG4 after 3 months of treatment were observed in both groups, independent of age. CONCLUSION: The accelerated SCIT regimen was revealed to be as safe as the conventional regimen, and the immunological effects of both regimens are similar. Accordingly, the accelerated regimen may be used to up-dose patients of adult as well adolescent age within 2 weeks.
Tipo de publicação: CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
Nome de substância:0 (Allergens); 0 (Antigens, Plant); 0 (Immunoglobulin G); 126161-14-6 (Bet v 1 allergen, Betula); 37341-29-0 (Immunoglobulin E)


  9 / 3005 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28331105
Título:JACQLQ (Japanese allergic conjunctival diseases Quality of Life Questionnaire).
Fonte:Arerugi; 66(2):120-121, 2017.
ISSN:0021-4884
País de publicação:Japan
Idioma:jpn
Tipo de publicação: JOURNAL ARTICLE


  10 / 3005 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
PMID:28296746
Autor:Wang X; Shi XD; Li LF; Zhou P; Shen YW; Song QK
Endereço:aDepartment of Dermatology, Beijing Friendship Hospital, Capital Medical University bDepartment of Dermatology, Beijing Shijitan Hospital, Capital Medical University cMarket Research Department, China Telecom Corporation Limited Beijing Research Institute, Beijing Future Science Park, Beijing, China.
Título:Prevalence and clinical features of adult atopic dermatitis in tertiary hospitals of China.
Fonte:Medicine (Baltimore); 96(11):e6317, 2017 Mar.
ISSN:1536-5964
País de publicação:United States
Idioma:eng
Resumo:The prevalence of atopic dermatitis (AD) has increased substantially. Previous studies have focused mostly on pediatric patients, while epidemiological investigation on adult AD has been very limited.The aim of this study was to determine the prevalence and clinical features of adult AD in outpatients with dermatitis and eczema in China mainland.A multicenter cross-sectional study was conducted among outpatients with eczema or dermatitis from 39 tertiary hospitals of 15 provinces in China from July 1 to September 30, 2014.Of 8758 patients, 407 were adult AD. Compared with adults with other types of dermatitis, the mean age (41.8 ±â€Š14.3 vs 42.04 ±â€Š15.38 years, P < 0.05) and onset age (35.2 ±â€Š11.2 vs 39.2 ±â€Š14.0 years, P < 0.001) of adult AD were younger, and mean disease duration was longer (5.3 ±â€Š7.1 vs 2.8 ±â€Š4.9 years, P < 0.001). About 53.3% adult AD involved 3 or more body locations, higher than adults with other types of dermatitis (34.4%, P < 0.001), but lower than those with pediatric and adolescent AD (73.8%, P < 0.001). History of asthma (19.2% vs 6.9%, P < 0.001) or allergic conjunctivitis (21.9% vs 14.9%, P < 0.05) was more common in adult AD than pediatric/adolescent AD. Suspected bacterial infection was more frequently in adult AD than adults with other types of dermatitis (24.3% vs 14.6%, P < 0.001) and pediatric/adolescent AD (24.3% vs 14.9%, P < 0.001). More severe itching was observed in 31.4% of adult AD, higher than that of adults with other types of dermatitis (15.4%, P < 0.001), whereas similar to that of pediatric/adolescent AD (28.7%, P > 0.05). The highest (8.7%) and lowest prevalence (3.7%) of adult AD were in 25°N to 30°N and 35°N to 40°N latitude region.A substantial part of adult outpatients with eczema or dermatitis is adult AD. Middle age, more body location involvement, more suspected bacterial infection, and severe itching are the main clinical feathers of adult AD. Geographical environment and economic situation work in synergy to adult AD.
Tipo de publicação: JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY



página 1 de 301 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde